Neurophet, a leading artificial intelligence (AI) company specializing in brain disorder diagnostics and treatment, announced its participation in the Alzheimer’s Disease and Parkinson’s Disease International Conference (AD/PD 2026) held in Copenhagen, Denmark, from March 17 to 21. The company showcased its brain imaging analysis products and presented two research abstracts on Alzheimer’s brain imaging analysis.
At the conference, Neurophet unveiled its comprehensive brain imaging analysis solution, Neurophet AQUA AD Plus, designed for prescribing Alzheimer’s treatments. This innovative software quantitatively analyzes magnetic resonance imaging (MRI) and positron emission tomography (PET) images to support clinical decision-making throughout the treatment process, from assessing patient eligibility to monitoring side effects and evaluating treatment efficacy.
Neurophet’s booth featured demonstrations of Neurophet AQUA AD Plus, along with its neurodegeneration imaging analysis software Neurophet AQUA and PET image quantification tool Neurophet SCALE PET.
The company also presented posters on cutting-edge research topics, including deep learning-based segmentation of ARIA and hemorrhagic lesions in brain amyloid angiopathy, as well as comparative studies of MR fusion and PET-only Centiloid analysis against Alzheimer’s Disease Neuroimaging Initiative (ADNI) benchmarks in amyloid PET imaging.
Neurophet’s participation in AD/PD 2026 aims to foster business development collaborations with global pharmaceutical giants, contract research organizations (CROs), and potential clients involved in Alzheimer’s treatment development.
The company highlighted its imaging core lab (ICL) services, which analyze neuroimaging biomarkers crucial for clinical trials in Alzheimer’s and Parkinson’s disease treatment development.
Bin Jun-gil, co-Chief Executive Officer (CEO) of Neurophet, stated that its Neurophet AQUA AD Plus is garnering significant attention from medical institutions worldwide for its advanced imaging analysis capabilities in Alzheimer’s treatment prescription. Through the presence at AD/PD 2026, they’re looking to expand strategic partnerships with key players in the pharmaceutical industry and drive tangible business outcomes in the near future.
